Cargando…
The antigen‐binding moiety in the driver's seat of CARs
Immuno‐oncology has been at the forefront of cancer treatment in recent decades. In particular immune checkpoint and chimeric antigen receptor (CAR)‐T cell therapy have achieved spectacular results. Over the years, CAR‐T cell development has followed a steady evolutionary path, focusing on increasin...
Autores principales: | Hanssens, Heleen, Meeus, Fien, De Veirman, Kim, Breckpot, Karine, Devoogdt, Nick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292017/ https://www.ncbi.nlm.nih.gov/pubmed/34028069 http://dx.doi.org/10.1002/med.21818 |
Ejemplares similares
-
Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019) -
Acute myeloid leukemia therapeutics: CARs in the driver’s seat
por: Mardiros, Armen, et al.
Publicado: (2013) -
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2021) -
Optimization of nonlinear quarter car suspension–seat–driver model
por: Nagarkar, Mahesh P., et al.
Publicado: (2016) -
Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT
por: Zeven, Katty, et al.
Publicado: (2023)